New hope for severe asthma: drug may tame immune attack on airways
NCT ID NCT05564078
First seen Jan 10, 2026 · Last updated May 23, 2026 · Updated 17 times
Summary
This study looked at 30 adults with severe asthma who did not get better with standard treatments. Researchers wanted to see if dupilumab, a drug that blocks certain immune signals, could reduce signs of the immune system attacking the airways. Participants took dupilumab for 4 months, and the team measured immune markers in the lungs before and after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AIRWAY AUTO IMMUNITY IN ASTHMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Research Institute of St. Joe's Hamilton
Hamilton, Ontario, L8N4A6, Canada
Conditions
Explore the condition pages connected to this study.